信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

交易中 07-30 13:16:45

104.600

+4.650

+4.65%

最高106.000	最低98.700	成交量2,488万
今开100.300	昨收99.950	日振幅7.30%
总市值1,788亿	流通市值1,788亿	总股本17.09亿
成交额25.58亿	换手率1.46%	流通股本17.09亿
市净率12.46	ROE-0.74%	每股收益-0.06
52周最高106.000	52周最低28.650	市盈率-1,645.22
股息0.00	股息收益率0.00	ROA-0.82%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":104.6,"timestamp":1753852601714,"preClose":99.95,"halted":0,"volume":24875903,"delay":0,"floatShares":1709000000,"shares":1709000000,"eps":-0.06357486486486487,"marketStatus":"交易中","change":4.65,"latestTime":"07-30 13:16:41","open":100.3,"high":106,"low":98.7,"amount":2557590820,"amplitude":0.073037,"askPrice":104.7,"askSize":42500,"bidPrice":104.5,"bidSize":11500,"shortable":3,"etf":0,"ttmEps":-0.0656019656019656,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1753863000000},"marketStatusCode":2,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":99.95,"openAndCloseTimeList":[[1753839000000,1753848000000],[1753851600000,1753862400000]],"volumeRatio":2.342282,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.6575,"impliedVolPercentile":0.8252},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2555709467","title":"狂砸4643亿！跨国巨头，正疯抢中国创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2555709467","media":"正解局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555709467?lang=zh_cn&edition=full","pubTime":"2025-07-30 12:05","pubTimestamp":1753848333,"startTime":"0","endTime":"0","summary":"葛兰素史克GSK收购恒瑞新药，只是跨国药企竞逐中国创新药的一个缩影。今年上半年，跨国药企狂砸4643亿元，掀起了一轮对中国创新药的“抢购热潮”。跨国药企外部采购管线来自中国企业的比例这表明，中国的创新药，越来越受到跨国药企的认可。麦肯锡2023年发布的相关报告指出，中国创新药的研发成本仅为美国同行的30%甚至20%。中国创新药BD交易总金额","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730121544a6c8f344&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730121544a6c8f344&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","LU2488822045.USD","01276","BK1583","BK1589","LU2328871848.SGD","01801","BK1161","09995","LU1969619763.USD"],"gpt_icon":0},{"id":"2555805287","title":"创新药，彻底疯了","url":"https://stock-news.laohu8.com/highlight/detail?id=2555805287","media":"北海茶客投研笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555805287?lang=zh_cn&edition=full","pubTime":"2025-07-29 21:31","pubTimestamp":1753795861,"startTime":"0","endTime":"0","summary":"为什么茶客今年能成功预言创新药会形成抱团式的爆炒？三股抱团势力创新药的交易节奏和市值版图首先，从基本面来讲，创新药这个行业是真正在发生剧变的行业，是AH两市中为数不多真正有产业趋势的行业。这一点茶客之前讲过很多：中国创新药崛起之谜：从科学到工程学中国的创新药，到底发展到什么阶段了？毕竟在公募基金这种聪明人扎堆内卷的机构，如果这一次不能证明自己，就永远没有下一次机会了。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729214931a469ce08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729214931a469ce08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","01276","BK0239","06160","02197","06628","688235","600276","01228","01801","09926","159992"],"gpt_icon":0},{"id":"2555037898","title":"北水动向|北水成交净买入127.2亿 北水再度加仓创新药概念 全天买入小米超16亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555037898","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555037898?lang=zh_cn&edition=full","pubTime":"2025-07-29 17:48","pubTimestamp":1753782521,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月29日港股市场，北水成交净买入127.2亿港元，其中港股通(沪)成交净买入58.78亿港元，港股通(深)成交净买入68.42亿港元。北水加仓创新药概念。石药集团、信达生物分别获净买入6.51亿、5.14亿港元。锦欣生殖获净买入1.94亿港元。方案明确，从2025年1月1日起，对符合法律法规规定生育的3周岁以下婴幼儿发放补贴，至其年满3周岁。此外，国泰君安国际获净买入4.3亿港元，而南方恒生科技遭净卖出6787万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072917562797252739&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072917562797252739&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","09988","00981","81810","LU2148510915.USD","01951","BK0214","01093","LU1064131003.USD","SGXZ49509284.SGD","SGXZ81163826.USD","01801","159992","688981"],"gpt_icon":1},{"id":"2555035386","title":"港股收评：午后回升！恒指小幅下跌0.15%，创新药涨幅抢眼，三胎概念股高开低走","url":"https://stock-news.laohu8.com/highlight/detail?id=2555035386","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555035386?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:21","pubTimestamp":1753777290,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["METmain","09618","601288","06160","161726","HSCEI","MPNGY","BIDU","01024","02359","159992","BABA","03690","01398","TTTN","HHImain","03086","07226","MHImain","YANG","601939","JD","TCHmain","KSTmain","603259","01288","01810","HSI","HSImain","TCEHY","08496","MCHmain","HTCD.SI","02186","01530","399441","MIUmain","01801","688428","HSTECH","09969","601398","00700","01093","ONC","00939","688235","ALBmain","06978"],"gpt_icon":0},{"id":"2555038763","title":"基金二季报陆续披露，中欧葛兰等基金经理加码创新药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2555038763","media":"全景网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555038763?lang=zh_cn&edition=full","pubTime":"2025-07-29 15:19","pubTimestamp":1753773595,"startTime":"0","endTime":"0","summary":"随着基金二季报陆续披露， 创新药 板块成为众多基金经理关注的焦点，葛兰、谢治宇、傅鹏博、高楠等基金经理也纷纷加码创新药板块。展望三季度，在创新药领域，中欧基金葛兰在二季报中表示，看好全球合作深化与重要临床数据披露预期。睿远基金傅鹏博在二季度增加了医药板块配置，涉及创新药等子行业；永赢基金高楠管理的永赢睿信，在将 康方生物 、百济神州- U买进重仓股后，还在继续加码创新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729152818a4691f68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729152818a4691f68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","ONC","BK4526","06160","BK4139","688235","01801"],"gpt_icon":0},{"id":"2555089892","title":"信达生物盘中异动 早盘股价大涨3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555089892","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555089892?lang=zh_cn&edition=full","pubTime":"2025-07-29 11:09","pubTimestamp":1753758572,"startTime":"0","endTime":"0","summary":"2025年07月29日早盘11时09分，信达生物股票出现波动，股价急速拉升3.04%。截至发稿，该股报96.750港元/股，成交量1037.74万股，换手率0.61%，振幅3.94%。资金方面，该股资金流入5.19562亿港元，流出3.05573亿港元。信达生物股票所在的药品行业中，整体跌幅为0.40%。该信息摘要如下：格隆汇7月28日｜香港交易所信息显示，贝莱德在信达生物的持股比例于07月22日从4.63%升至5.19%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072911093297246f8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072911093297246f8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2328871848.SGD","01801","LU1969619763.USD","BK1583","BK1589","LU2488822045.USD"],"gpt_icon":0},{"id":"2554272096","title":"贝莱德：在信达生物的持股比例升至5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554272096","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554272096?lang=zh_cn&edition=full","pubTime":"2025-07-28 17:06","pubTimestamp":1753693599,"startTime":"0","endTime":"0","summary":"格隆汇7月28日｜香港交易所信息显示，贝莱德在信达生物的持股比例于07月22日从4.63%升至5.19%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072817085194bf062b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072817085194bf062b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","BK1589","LU2328871848.SGD","BK1161","LU2488822045.USD","01801"],"gpt_icon":0},{"id":"2554242097","title":"东方证券：小核酸药物治疗潜力显现 关注潜在BD机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2554242097","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554242097?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:52","pubTimestamp":1753692765,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，小核酸药物能解决小分子和抗体等传统药物不能解决的临床需求，极有可能成为产生大量产品的新技术路径。随着小核酸药物在常见慢病领域治疗潜力的释放，未来有望持续诞生重磅BD。风险提示创新药研发失败风险、市场竞争加剧导致产品大幅降价风险、产品销售和BD不及预期的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","IE00BZ08YS42.EUR","03958","BK1147","600958","BK1564","BK0276","IE00BZ08YT58.USD","BK1589","LU2488822045.USD","BK1583","BK0028","LU2328871848.SGD","BK1521","LU1969619763.USD","BK0183","BK1515","BK0012","IE00BZ08YR35.GBP","01801","01177","BK1191","BK1161"],"gpt_icon":0},{"id":"2554672566","title":"港股异动 | 创新药概念多数走高 行业迎政策红利密集释放期 BD有望加速创新药重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2554672566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554672566?lang=zh_cn&edition=full","pubTime":"2025-07-28 14:52","pubTimestamp":1753685525,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1997244956.HKD","LU1997245094.SGD","LU1064131003.USD","03692","BK0196","LU2148510915.USD","BK1521","LU2328871848.SGD","BK0239","600276","LU1969619763.USD","BK0188","LU2495084118.USD","BK1583","BK1515","LU1655091616.SGD","159992","LU0405327148.USD","LU2488822045.USD","06978","BK0012","BK0183","LU0405327494.USD","BK1593","LU1064130708.USD","02096","BK0028","01801","BK0060","01530","BK1191","BK1161","BK1574","LU1997245177.USD","BK1589","01276","IE00BZ08YT58.USD","01177","LU1328615791.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2554235767","title":"【券商聚焦】中信建投维持信达生物“买入”评级 指其在肿瘤赛道的广泛布局已初具规模","url":"https://stock-news.laohu8.com/highlight/detail?id=2554235767","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554235767?lang=zh_cn&edition=full","pubTime":"2025-07-28 13:38","pubTimestamp":1753681084,"startTime":"0","endTime":"0","summary":"该机构指，公司在肿瘤赛道的广泛布局已初具规模，高价值的临床产品有望将公司肿瘤赛道的收入进一步提升并让边际成本持续下降；非肿瘤赛道中，公司已在代谢、自免和眼科领域进行广泛布局，已上市与在研产品兼具竞争力强和进度领先。维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728135909a4670b03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728135909a4670b03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801"],"gpt_icon":0},{"id":"2554500737","title":"创新药暴涨之后到位了吗？汇丰：下半年还有三大催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2554500737","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554500737?lang=zh_cn&edition=full","pubTime":"2025-07-25 11:37","pubTimestamp":1753414629,"startTime":"0","endTime":"0","summary":"汇丰认为，下半年即将密集公布的学术成果、持续涌现的海外业务发展（BD）交易，以及政策面的支持将支撑医药板块的上涨势头。中国创新药企的价值潜力尚未被市场完全消化，未来仍有进一步上行空间。","market":"us","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3751855","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3751855","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4521","LU0310800965.SGD","LU0128525689.USD","BK1161","03692","01177","BK1574","LU0052756011.USD","LU1267930227.SGD","BK4585","01801","BK4588","02269","LU2236285917.USD","BK4207"],"gpt_icon":1},{"id":"2553078322","title":"新事丨罗氏终止TIGIT全部三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553078322","media":"健识局","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553078322?lang=zh_cn&edition=full","pubTime":"2025-07-24 20:30","pubTimestamp":1753360205,"startTime":"0","endTime":"0","summary":"在最新的管线中，PD-1联合TIGIT治疗非小细胞肺癌、肝癌的三期临床均已终止。这意味着罗氏针对TIGIT进行的三期临床全部终止。TIGIT靶点的价值是罗氏在2009年最先发现的。当时，罗氏的TIGIT+PD-L1联合疗法的效果曾一鸣惊人，一度被认为是PD-1之后的免疫新星。全球范围内，这几年TIGIT单抗预期快速变化：默沙东、罗氏等药企都已经历多次失败，留给TIGIT靶点成功的希望相当渺茫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRK","BK0012","01276","LU0405327494.USD","BK0196","LU1997245094.SGD","LU2148510915.USD","LU0405327148.USD","01801","LU1969619763.USD","LU2495084118.USD","LU1064131003.USD","BK0239","688266","LU1997244956.HKD","BK0183","LU1328615791.USD","688235","LU1064130708.USD","688177","06160","LU2488822045.USD","600276","BK0028","LU1655091616.SGD","LU1997245177.USD","LU2328871848.SGD","BK0188","ONC","BK0060"],"gpt_icon":1},{"id":"2553476116","title":"年内“冠军基”最新持仓曝光 这只股票“晋升”第一大重仓股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553476116","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553476116?lang=zh_cn&edition=full","pubTime":"2025-07-21 19:02","pubTimestamp":1753095742,"startTime":"0","endTime":"0","summary":"近期，公募基金二季报密集披露，绩优基金的最新调仓动态随之曝光。7月21日，年内“冠军基”汇添富香港优势精选发布2025年二季报，公告显示，该基金在二季度提高了股票仓位，加仓了映恩生物、三生制药、石药集团，其中映恩生物位列第一大重仓股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1345,202507213462970925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["BK1583","BK1574","BK1161","LU2328871848.SGD","BK1589","01801","06978","399300","159982","LU2488822045.USD","LU1969619763.USD"],"gpt_icon":0},{"id":"2553479985","title":"基金2季报收官，公募对AI和创新药的“偏爱”，藏都不藏了","url":"https://stock-news.laohu8.com/highlight/detail?id=2553479985","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553479985?lang=zh_cn&edition=full","pubTime":"2025-07-21 18:08","pubTimestamp":1753092480,"startTime":"0","endTime":"0","summary":"来源：华尔街见闻抄底AI和创新药2025年公募基金2季报，日前全部发布完毕。在这个转折的季节，公募基金对A股的偏好和增减仓，态度十分明显。根据WIND对截至7月21日下午4点的发布统计，公募基金年中的十大重仓股中，AI概念股大获追捧。此外，创新药企业也迎来了不少基金经理的“追捧”。尤其值得一提的是，主动公募基金对中际旭创、新易盛的持股总市值，在2季度增长了百亿元以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721193108a4596751&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721193108a4596751&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","09988","00300","00981","CVM","600519","ZIJMY","01810","01801","02899","601899","688981","06936","ZIJMF","BK4017","600760","03750","01530"],"gpt_icon":0},{"id":"2553473434","title":"贝莱德：在信达生物的持股比例升至5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553473434","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553473434?lang=zh_cn&edition=full","pubTime":"2025-07-21 17:07","pubTimestamp":1753088845,"startTime":"0","endTime":"0","summary":"格隆汇7月21日｜香港交易所信息显示，贝莱德在信达生物的持股比例于07月15日从4.78%升至5.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072117081497ae74ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072117081497ae74ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01801","LU2328871848.SGD","BK1161","LU2488822045.USD","LU1969619763.USD","BK1589"],"gpt_icon":0},{"id":"2553842793","title":"葛兰、谢治宇最新持仓曝光：共同聚焦创新药，这些个股被重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2553842793","media":"每经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553842793?lang=zh_cn&edition=full","pubTime":"2025-07-21 16:56","pubTimestamp":1753088193,"startTime":"0","endTime":"0","summary":"另外，兴证全球基金谢治宇管理的兴全合润，二季度减持了比亚迪、海尔智家，转而重仓分众传媒、蓝思科技。葛兰二季度加码创新药先从中欧医疗健康来看，二季度虽然出现净赎回的情况，但整体份额依然超过185亿份，规模超过300亿元。整体来看，创新药行业的持仓个股数量进一步增加，而多只医疗个股、中药个股已不见身影。可以看出，谢治宇二季度也偏爱创新药，重仓了多只个股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165943a459004f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165943a459004f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BYDDY","BK0188","01530","03347","BK0028","688428","600160","01415","BK0196","159992","688235","01211","03750","BK0044","81211","06690","BK0229","09969","06613","600690","01801","BK0015","688099","03759"],"gpt_icon":0},{"id":"2553436473","title":"信达生物07月21日遭主力抛售1618.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553436473","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553436473?lang=zh_cn&edition=full","pubTime":"2025-07-21 16:16","pubTimestamp":1753085762,"startTime":"0","endTime":"0","summary":"07月21日, 信达生物股价跌0.45%，报收88.65元，成交金额9.3亿元，换手率0.61%，振幅4.38%，量比0.56。信达生物今日主力资金净流出1618.4万元，上一交易日主力净流出495.4万元。该股近5个交易日上涨8.72%，主力资金累计净流入1.7亿元；近20日主力资金累计净流入3.8亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721170256a6b78f18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721170256a6b78f18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2328871848.SGD","BK1589","01801","LU1969619763.USD","BK1161","BK1583"],"gpt_icon":0},{"id":"2553216454","title":"一图速览Q2基金持仓变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2553216454","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553216454?lang=zh_cn&edition=full","pubTime":"2025-07-21 15:46","pubTimestamp":1753083961,"startTime":"0","endTime":"0","summary":"25Q2基金持仓有何变化？","market":"hk","thumbnail":"https://img3.gelonghui.com/0c859-a7b88c71-79a3-4043-b704-e9d2f0cb83af.jpg?guru_height=3339&guru_width=6010&guru_size=899485","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/0c859-a7b88c71-79a3-4043-b704-e9d2f0cb83af.jpg?guru_height=3339&guru_width=6010&guru_size=899485"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2522815","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0823041008.USD","LU0918141887.USD","LU0228367735.SGD","LU0149721374.USD","LU2251237488.HKD","09992","LU0862451753.SGD","LU1105468828.SGD","LU0540923850.HKD","01530","LU0106252389.USD","LU1725190679.HKD","LU2087589342.USD","LU0165289439.USD","LU0149534421.HKD","TCHmain","ALBmain","LU0320764755.SGD","LU0449515922.USD","002463","LU0455707207.USD","LU0577902298.EUR","LU0106259558.USD","LU0254981946.USD","00700","LU1568876251.USD","01801","LU1956131251.USD","LU2008162690.USD","LU1769817096.USD","SG9999006597.SGD","LU0516422952.EUR","LU0572944931.SGD","LU1481107354.HKD","BABA","IE00B543WZ88.USD","BK4543","LU1152091168.USD","LU2580892789.USD","LU1303224171.USD","HTCD.SI","LU1235294995.USD","09988","300502","LU1868838027.USD","LU1242518931.SGD","BK1589","LU1044874839.SGD","300476","300308"],"gpt_icon":1},{"id":"1171878852","title":"港股通与恒指8月调整预览：泡泡玛特、信达生物等位列符合纳入恒指名单前列，AH两地上市公司在稳价期可直接入通","url":"https://stock-news.laohu8.com/highlight/detail?id=1171878852","media":"中金点睛","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171878852?lang=zh_cn&edition=full","pubTime":"2025-07-21 07:54","pubTimestamp":1753055678,"startTime":"0","endTime":"0","summary":"港股通调整：预计19只公司有望入通，另有17只或被移出；AH两地上市公司在稳价期可直接入通此次调整也适逢恒生综合指数的半年度指数审议。今年6月23日港股上市的三花智控由于其AH两地上市公司性质，也会在近日随30日价格稳定期结束后直接纳入港股通交易。此外，7月最新登陆港股的AH两地上市公司如安井食品、蓝思科技以及FORTIOR也将在8月稳价期结束后纳入港股通。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/ddc1f1fb995e1663f4639b8e8d9b1796","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/ddc1f1fb995e1663f4639b8e8d9b1796"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/8MXin3LsCpHp6oz8PvMFGQ","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zjdj","symbols":["01801","09987","HSI","09868","01179","09992"],"gpt_icon":1},{"id":"2553441925","title":"汇添富基金乐无穹旗下汇添富国证港股通创新药ETF中报最新持仓，重仓信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2553441925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553441925?lang=zh_cn&edition=full","pubTime":"2025-07-21 07:08","pubTimestamp":1753052913,"startTime":"0","endTime":"0","summary":"证券之星消息，7月21日汇添富基金旗下乐无穹管理的汇添富国证港股通创新药交易型开放式指数基金公布中报，近1年净值增长率122.45%。与上一季度相比，该基金前十大重仓股新增亚盛医药-B；并对信达生物增仓604.75万股，为该基金第一大重仓股；联邦制药等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072100001482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1161","LU2328871848.SGD","BK1589","HSTECH","01801","515120","HSCEI","LU2488822045.USD","LU1969619763.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.141},{"period":"1month","weight":0.2922},{"period":"3month","weight":0.8595},{"period":"6month","weight":2.0242},{"period":"1year","weight":1.6725},{"period":"ytd","weight":1.7309}],"compareEarnings":[{"period":"1week","weight":0.0157},{"period":"1month","weight":0.0511},{"period":"3month","weight":0.1539},{"period":"6month","weight":0.262},{"period":"1year","weight":0.4807},{"period":"ytd","weight":0.2724}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.056031},{"month":2,"riseRate":0.714286,"avgChangeRate":0.11927},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.013609},{"month":8,"riseRate":0.833333,"avgChangeRate":0.002206},{"month":9,"riseRate":0.666667,"avgChangeRate":0.03832},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.010418},{"month":11,"riseRate":0.571429,"avgChangeRate":0.078824},{"month":12,"riseRate":0.428571,"avgChangeRate":0.054557}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}